ARL67156 trisodium hydrate (C007B-326451)

ARL67156 (FPL 67156) trisodium hydrate is a selective ecto-ATPase inhibitor. ARL67156 trisodium hydrate is a competitive inhibitor of NTPDase1 (CD39), NTPDase3 and NPP1, with K i s of 11, 18 and 12 μM, respectively. ARL67156 trisodium hydrate can be usedAppearance:SolidIC50& Target:Ki: 11 μM (NTPDase1), 18 μM (NTPDase3), 12 μM (NPP1)In Vitro:ARL67156 trisodium hydrate (1-100 μM) potentiates neurogenic contractions in a concentration-dependent manner. ARL67156 trisodium hydrate (10 μg/mL, 24 h) increases the surface expression of CXCR3 on ATP-treated HMC-1 cells. ARL67156 trisodium hIn Vivo:ARL67156 trisodium hydrate (1.1 μg/kg/day, administered with osmotic pumps implanted subcutaneously, for 28 days) prevents the development of calcific aortic valve disease in Warfarin (HY-B0687)-treated rats. ARL67156 trisodium hydrate (intraperitoneBiological Activity:ARL67156 (FPL 67156) trisodium hydrate is a selective ecto-ATPase inhibitor. ARL67156 trisodium hydrate is a competitive inhibitor of NTPDase1 (CD39), NTPDase3 and NPP1, with K i s of 11, 18 and 12u2009μM, respectively. ARL67156 trisodium hydrate can be u.

Specifications and Purity: ≥99%

Molecular Formula: C15H23Br2N5Na3O13P3

Molecular Weight: 834.61